1 / 6

Bevacizumab (AVASTIN) in every day practice - one year experience -

Bevacizumab (AVASTIN) in every day practice - one year experience -. Dzinic V, Dzinic M, Oros A. Private Eye Clinic “Prof dr Dzinic”, Clinical center Vojvodine University Eye Clinic Novi Sad, Serbia. Purpose:.

jopayne
Télécharger la présentation

Bevacizumab (AVASTIN) in every day practice - one year experience -

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Bevacizumab (AVASTIN) in every day practice - one year experience - Dzinic V, Dzinic M, Oros A Private Eye Clinic “Prof dr Dzinic”, Clinical center Vojvodine University Eye Clinic Novi Sad, Serbia

  2. Purpose: to investigate the effects of intravitreal anti-VEFG (bevacizumab) application in patients with wet AMD, DME and CRVO in every day condition in the setting where it is very difficult to establish and follow injections protocol, number of applications and adequate timing.

  3. Material and methods: 56 eyes (48 patients) were followed during 12 months; Mean age was 70 (from 51 to 88 years); Diagnosis of wet AMD, DME, and CRVO were established; All patients received one intravitreal injection 0.05ml (1.25mg) of bevacizumab (Avastin); Macular thickness were evaluated with SD-OCT at follow up visits conducted at the first and 7th day after injection and every 4-6 weeks after. Last follow up visit was 9-12 months after injection; All patients used non steroid local therapy (NSAID) 4-6 weeks after injection:

  4. Results: Patients were divided into groups depending on underlying disease; Mean VA before treatment was 0.214 ± 0.23; At the last follow up (9-12 months after injection) average VA was 0.304 ± 0.21; Average macular thickness before treatment was 367.2µm±98µm; At the last follow up (9-12 months after injection) macular thickness was 330.07µm±80µm.

  5. Results:

  6. Conclusion: Intravitreal application of bevacizumab have beneficial effects in every day practice; In properly selected patients despite the problems of appropriate timing and proper number of injection, results in general show statistically significant improvement in VA and macular thickness (p<0.01) during follow up period.

More Related